Case Report: Liver Metastasis from Ductal Carcinoma In Situ of the Breast Authors: Weiya Zhuang, Daozhe Lin, Chengliang Chen Published: 2026 ABSTRACT PurposeThis article reports a rare case of liver metastasis in a patient with breast ductal carcinoma in situ (DCIS) after surgery, aiming to emphasize the rarity and potential metastatic risk of DCIS, especially liver metastasis, and provide reference for clinical diagnosis and treatment.Patients and MethodsThe clinical data of a 35-year-old female patient with liver metastasis from DCIS admitted to our hospital were collected, and the latest literature and clinical guidelines were systematically reviewed.ResultsThe patient was diagnosed with high-grade, HER2-positive, large-volume (5.0 cm × 3.5 cm) DCIS (TisN0M0) in September 2021. Liver metastasis was confirmed 5 months after surgery. After 10 cycles of TCbHP regimen (docetaxel + carboplatin + trastuzumab + pertuzumab), liver metastases achieved complete remission. Subsequent maintenance therapy with HP combined with capecitabine maintained stable disease without recurrence.ConclusionDistant metastasis of DCIS is extremely rare but can occur in high-risk populations. High-grade, large tumor size (>3 cm), HER2 positivity, and high Ki-67 are independent high-risk factors with moderate-to-high evidence levels. Early identification of high-risk DCIS and active anti-HER2 targeted combination therapy can significantly improve the prognosis of metastatic patients. Introduction Breast cancer is the most common malignant tumor in women worldwide with high morbidity and mortality.1 Ductal carcinoma in situ (DCIS) is defined as a malignant proliferation of ductal epithelial cells confined within the basement membrane, belonging to non-invasive breast cancer (stage 0).2 Breast cancer statistics show that DCIS accounts for a considerable proportion of newly diagnosed breast cancer cases,3 and its biological behavior and metastatic potential have been a research focus in recent years.4 Distant metastasis of DCIS is an extremely rare event with an incidence of less than 0.5%, and liver metastasis is even rarer.5 The balance between overtreatment and undertreatment of DCIS has always been a clinical focus, and the rare occurrence of distant metastasis further complicates this balance.6 Although DCIS is traditionally considered to have no metastatic potential, increasing case reports have confirmed that distant metastasis, especially liver metastasis, can occur in a few high-risk DCIS patients.7,8 The rarity of DCIS liver metastasis leads to insufficient clinical awareness, unclear risk stratification, and lack of standardized treatment strategies.9 DCIS accounts for approximately 30% of newly diagnosed breast cancer cases.10 Most DCIS patients have a favorable prognosis after surgical treatment, but a small number of high-risk patients may develop early distant metastasis, which is related to missed microinvasion, high nuclear grade, large tumor size, and HER2 positivity.11,12 The epidemiology of liver metastases in breast cancer has been studied, but data on DCIS-related liver metastasis are extremely limited.13 Due to the extreme rarity of DCIS liver metastasis, there is still a lack of systematic literature summary and unified treatment norms.14 Dietary interventions and metabolic regulation may have potential implications for liver metastatic breast cancer, but their role in DCIS-related liver metastasis remains unclear.15 This paper reports a rare case of liver metastasis after surgery for high-grade, HER2-positive, large-volume DCIS, emphasizes the metastatic potential and rarity of DCIS, summarizes the high-risk factors and evidence levels of DCIS distant metastasis, and analyzes the efficacy of TCbHP regimen, aiming to improve clinicians’ awareness and diagnosis-treatment level of this rare event.16 Case Presentation General Information A 35-year-old premenopausal married female was admitted due to “left breast mass for 2 months”. Height 160 cm, weight 65 kg, BMI 25.4 kg/m2. No smoking, drinking, toxic exposure, or family history of malignant tumors. Physical examination: a 4 cm × 4 cm mass in the upper inner quadrant of the left breast, medium hard texture, clear boundary, no tenderness, good mobility, no adhesion to skin. Radiological examination of the breast has certain guiding significance for the diagnosis of DCIS, and this patient’s imaging features were consistent with high-risk DCIS manifestations.10 Diagnosis and Treatment Process Initial diagnosis and surgery: On September 24, 2021, left breast tumor segmentectomy was performed; postoperative pathology suggested DCIS. Interobserver variability in DCIS diagnosis should be noted, and multiple sections were examined to ensure diagnostic accuracy.11 On October 12, 2021, “left simple mastectomy + left sentinel lymph node biopsy” was performed. Pathological results: High-grade DCIS (5.0 cm × 3.5 cm); IHC: ER(−), PR(−), HER-2(2+), Ki-67(30%+); FISH positive; pathological stage TisN0M0. Some DCIS cases may present with DCIS-like invasive ductal carcinoma, but this case was confirmed as pure DCIS without invasive components.12 The pathological features of DCIS, including nuclear grade and tumor size, are important prognostic factors.14 No adjuvant therapy was given postoperatively. Metastasis diagnosis: In January 2022, follow-up abdominal ultrasound found multiple hepatic space-occupying lesions; enhanced MRI suggested multiple metastatic tumors. Liver puncture on March 2, 2022, confirmed adenocarcinoma, consistent with breast cancer origin (IHC: ER(−), PR(−), C-erbB2(2+), Ki-67(40%+), FISH positive). Liver metastasis occurred about 5 months after surgery. Similar cases of distant metastasis after mastectomy for DCIS have been reported, but liver metastasis is still relatively rare.17 Treatment plan: Implantable venous port was placed, and TCbHP regimen was started on March 21, 2022 (docetaxel 130 mg + carboplatin 690 mg + trastuzumab 390 mg [initial dose 520 mg] + pertuzumab 420 mg [initial dose 840 mg], q3w). After 10 cycles, maintenance therapy was given: trastuzumab 390 mg + pertuzumab 420 mg + capecitabine 1.5 g bid. Integrative studies on key genes driving DCIS progression have provided a theoretical basis for targeted therapy.18 Efficacy: After 10 cycles of TCbHP, liver metastases achieved complete remission (CR); maintenance therapy showed stable disease (SD) without recurrence. The evolution of DCIS treatment has emphasized the importance of stratified management, and targeted therapy for high-risk DCIS has gradually become a research focus.19 Auxiliary Examinations Tumor markers: Abnormal elevation during metastasis, which returned to normal after treatment (Table 1).Table 1Tumor Markers From September 22, 2021 to October 5, 2022Time/ItemAFP (ng/mL)CEA (ng/mL)CA125 (U/mL)CA153 (U/mL)CA724 (U/mL)2021-9-225.5117.487.77/2022-2-246.132.788.8117.176.652022-3-28/1.316.7818.79/2022-4-186.640.69.7217.7961.212022-5-106.7<0.57.0621.1698.422022-5-317.520.816.3317.84>3002022-6-2////>3002022-6-216.88<0.56.5719.3281.162022-7-127.63<0.56.1616.2555.062022-8-37.440.615.615115.52022-8-267.060.72515.463.432022-9-156.13<0.5512.951.52022-10-55.93<0.55.612.743.24 Table 1Tumor Markers From September 22, 2021 to October 5, 2022Time/ItemAFP (ng/mL)CEA (ng/mL)CA125 (U/mL)CA153 (U/mL)CA724 (U/mL)2021-9-225.5117.487.77/2022-2-246.132.788.8117.176.652022-3-28/1.316.7818.79/2022-4-186.640.69.7217.7961.212022-5-106.7<0.57.0621.1698.422022-5-317.520.816.3317.84>3002022-6-2////>3002022-6-216.88<0.56.5719.3281.162022-7-127.63<0.56.1616.2555.062022-8-37.440.615.615115.52022-8-267.060.72515.463.432022-9-156.13<0.5512.951.52022-10-55.93<0.55.612.743.24 Tumor Markers From September 22, 2021 to October 5, 2022 Imaging: Breast ultrasound (BI-RADS 4A) and mammography (BI-RADS 4B) suggested malignant lesions; abdominal ultrasound and enhanced MRI showed multiple liver metastases (Figures 1–13). Radiological examination plays an important role in the follow-up and metastasis detection of DCIS.10Figure 1Ultrasonography revealed a patchy hypoechoic area in the left breast, assessed as BI-RADS category 4A, two dotted lines reveal the maximum cross-sectional area of the tumor.Grayscale ultrasound showing tissue layers and crosshair calipers on dark background.A grayscale ultrasound image features a dark background with horizontal, wavy, layered bands in varying gray tones at the top, creating a stratified texture. The center shows a darker, irregular area surrounded by mid-gray tissue. A measurement overlay with two dotted perpendicular lines forms a crosshair, with the horizontal line extending across the center and the vertical line running from near the top to the bottom. Both lines end with plus-shaped endpoints. The intersection is centered over the darker area. No labels or numeric values are present. A circular icon with concentric rings is in the bottom-right corner.Figure 2Mammography revealed regional, diffuse, fine pleomorphic calcifications in the medial left breast, for which malignancy could not be excluded, warranting further investigation (BI-RADS 4B). The right breast showed focal asymmetry in the lower breast, recommended for short-term follow-up (BI-RADS 3).A grayscale radiograph shows a dense, cloud-like tissue mass with scattered bright specks on a black background.A grayscale radiographic image occupies the center-right of the frame, with a solid black background surrounding it. The left edge contains a vertical black margin. The main subject is an irregular, rounded wedge-shaped region of overlapping gray and white densities, forming a cloud-like texture with layered, wispy streaks and mottled patches. Brighter white areas concentrate toward the lower half and central region, while darker gray regions and faint streaks extend toward the upper portion. Numerous small, discrete bright specks are scattered across the lower half and lower-left portion of the dense region, forming a loose cluster of punctate points. No axis markings, scale bars, labels, arrows, or text annotations are present.Figure 3Abdominal Ultrasound Image (20 January 2022). The dotted line is used to measure the maximum cross-sectional distance of the lesion, and (+) indicates the starting and ending points of the measurement.Ultrasound shows grayscale tissue with four markers outlining an oval on a dark background.An ultrasound image in a wedge-shaped sector with a curved bright band along the top edge and a black background outside the sector. The interior contains mottled grayscale soft tissue texture with scattered brighter linear echoes near the upper portion. In the mid-to-right area, four caliper cross markers form a rectangular measurement frame around an oval region. A dotted trace connects the calipers, outlining the oval shape. The left side of the sector contains darker grayscale tissue, while the lower portion contains a brighter curved boundary line extending across the bottom.Figure 4Abdominal Ultrasound Image (26 February 2022). The dotted line is used to measure the maximum cross-sectional distance of the lesion, and (+) indicates the starting and ending points of the measurement.Ultrasound image: grayscale tissue with crosshairs marking a central area on a dark background.An ultrasound micrograph with a wedge-shaped grayscale scan area on a black background. The upper edge of the wedge has a bright curved boundary with layered bright and dark bands beneath it. The central area contains four crosshair markers arranged around a roughly rectangular region, with one crosshair near the upper center, one near the left center, one near the lower center and one near the right center. Between the left and right crosshair markers, a horizontal dotted line runs across the central region. A bright, irregular reflective area occupies the lower central portion of the wedge, with a brighter curved band extending along the lower left edge. Along the right side, a vertical depth scale includes numeric labels “0”, “5” and “10”, with small tick marks between them. Near the right margin, a vertical bracket graphic spans part of the depth scale and the text “x3” is printed adjacent to the bracket.Figure 5Abdominal Ultrasound Image (1 June 2022).Grayscale ultrasound: sector scan, right depth scale, 4-marker caliper on speckled tissue.A grayscale ultrasound image with a sector-shaped scan field on a black background. The scan field contains speckled gray soft-tissue texture with multiple small dark round and oval areas scattered across the left and central regions. A caliper measurement marker made of four plus-sign markers forms a small square in the left-middle portion of the scan field, positioned over a small dark rounded area. A brighter curved band runs along the lower-left edge of the scan field, with darker shadowed regions adjacent to it. Along the right side, a vertical depth scale is present with tick marks and numeric labels at zero, negative five and negative ten.Figure 6Contrast-enhanced abdominal magnetic resonance image (22 February 2022).Axial scan shows abdominal soft tissues with two bright spots and a dark background.A grayscale axial radiology image presents a cross-sectional view of the upper abdomen centered within a dark background. The body outline forms an oval contour with a thin brighter rim at the periphery. Inside the section, multiple soft-tissue regions of differing gray intensity occupy the left and right halves. Near the midline, a rounded bright structure sits anterior to a darker central region. Two additional rounded bright foci are present: one smaller focus within the left-sided soft-tissue region and another brighter, irregularly shaped focus within the right-sided soft-tissue region. Posteriorly, a central circular bright point lies near the midline, surrounded by darker and mid-gray tissues. No scale bar, magnification text, staining information, axis labels, or graph elements are present.Figure 7Contrast-enhanced abdominal magnetic resonance image (20 April 2022).Grayscale MRI of upper abdomen showing two large organs and central vertebra on dark background.A grayscale axial magnetic resonance image slice of the upper abdomen on a dark background. Two large solid soft-tissue organs occupy most of the central field, separated by a curved interface. The organ on the left side of the frame has a relatively uniform mid-gray signal with a few small brighter foci. The organ on the right side of the frame contains a broad, brighter wedge-shaped region along its lateral portion with darker gray tissue medially. A bright oval structure lies near the midline anterior to the spine. Posteriorly, a rounded vertebral body sits near the center with a bright circular focus within the spinal canal region. Curved bands of soft tissue and fat outline the body wall circumferentially, with darker peripheral margins at the edges of the slice. No text labels, scale bars, or annotations are present.Figure 8Contrast-enhanced abdominal magnetic resonance image (1 June 2022).Axial MRI of upper abdomen: bright fluid signal, dark background.A grayscale axial magnetic resonance slice through the upper abdomen on a dark background. A large, medium-gray organ occupies most of the left side of the frame, containing several small brighter foci and one larger bright focus near the upper central region. On the right side of the frame, a rounded structure contains a prominent bright crescent-shaped region along its inner portion, bordered by darker soft tissue. Posteriorly near the midline, a round vertebral body structure is present with a bright circular focus within the spinal canal region. Curved rib and paraspinal soft-tissue contours outline the posterior thorax and upper abdominal wall, with subcutaneous fat forming a thin peripheral rim.Figure 9Contrast-enhanced abdominal magnetic resonance image (14 July 2022).Photograph of an axial contrast-enhanced abdominal magnetic resonance image cross-section.The frame shows the upper abdomen with a large organ occupying much of the left side of the frame and another organ on the right side of the frame. A rounded vertebral body is centered near the lower portion of the frame, with surrounding soft tissue structures. Several small, bright focal spots are present within the large organ on the left side of the frame. Curved body contours and layered soft tissues form the outer boundary of the cross-section.Figure 10Contrast-enhanced abdominal magnetic resonance image (6 August 2022).A grayscale axial magnetic resonance image of the upper abdomen with the liver and spleen on a dark background.A grayscale axial magnetic resonance image slice through the upper abdomen on a dark background. A large, medium-gray organ occupies most of the left side of the image, with fine internal gray texture and scattered small brighter foci. A smaller, brighter gray organ occupies the right side of the image with a smoother internal texture. A round vertebral body structure lies near the center-bottom with a bright circular rim and darker center and adjacent darker soft-tissue structures around it. Curved dark bands outline the body wall, with surrounding soft tissues forming an oval cross-sectional contour. No text labels, scale bars, legends, or measurement markings are present.Figure 11Contrast-enhanced abdominal magnetic resonance image (7 October 2022).A grayscale axial abdominal magnetic resonance image with soft-tissue contrast and a dark peripheral background.A grayscale axial abdominal magnetic resonance image slice with a dark background surrounding the body outline. The central region contains multiple soft-tissue structures with varied gray intensities. A large, heterogeneous mid-gray organ occupies much of the left side of the slice, containing scattered small brighter foci. On the right side, a rounded structure with a brighter internal region and a darker rim lies adjacent to the midline. Near the posterior midline, a circular bright ring structure is present within a darker surrounding area. Curved bright linear margins outline portions of the right-sided rounded structure and adjacent boundaries. No overlaid text, arrows, scale bars, or label lines are present.Figure 12Contrast-enhanced abdominal magnetic resonance image (3 December 2022).Grayscale MRI of upper abdomen showing soft tissue contrast on dark background.A grayscale axial magnetic resonance image slice centered within a rectangular frame. The background is uniformly dark gray to black. An oval cross-sectional body outline occupies the central area, bordered by a thin brighter rim. Within the oval region, multiple soft-tissue structures of differing gray intensities form a heterogeneous pattern. A large, relatively uniform mid-gray region occupies much of the left side of the oval. On the right side, a brighter curved region forms a crescent-like shape adjacent to a mottled, speckled area with mixed light and dark gray texture. Near the lower central portion, a small bright circular focus is present, surrounded by darker gray tissue. No text labels, scale bars, magnification markings, arrows, callouts, axes, plotted curves, numeric scales, or measurement units are present.Figure 13Contrast-enhanced abdominal magnetic resonance image (7 February 2023).Axial MRI of upper abdomen: liver left, spleen right, on dark background.A grayscale axial magnetic resonance image slice through the upper abdomen on a dark background. A large, medium-gray organ occupies most of the left half of the body cross-section. On the right half, a smaller, brighter organ is present with a curved outer margin. Between these organs, a bright curved region is present near the upper right portion of the abdominal cavity. Posteriorly near the midline, a round vertebral body is present with a bright central area and adjacent posterior elements are present. A thin bright rim outlines portions of the body wall and surrounding soft tissues form a continuous oval contour around the abdominal contents. No text labels, scale bars, or measurement markings are present. Ultrasonography revealed a patchy hypoechoic area in the left breast, assessed as BI-RADS category 4A, two dotted lines reveal the maximum cross-sectional area of the tumor. Mammography revealed regional, diffuse, fine pleomorphic calcifications in the medial left breast, for which malignancy could not be excluded, warranting further investigation (BI-RADS 4B). The right breast showed focal asymmetry in the lower breast, recommended for short-term follow-up (BI-RADS 3). Abdominal Ultrasound Image (20 January 2022). The dotted line is used to measure the maximum cross-sectional distance of the lesion, and (+) indicates the starting and ending points of the measurement. Abdominal Ultrasound Image (26 February 2022). The dotted line is used to measure the maximum cross-sectional distance of the lesion, and (+) indicates the starting and ending points of the measurement. Abdominal Ultrasound Image (1 June 2022). Contrast-enhanced abdominal magnetic resonance image (22 February 2022). Contrast-enhanced abdominal magnetic resonance image (20 April 2022). Contrast-enhanced abdominal magnetic resonance image (1 June 2022). Contrast-enhanced abdominal magnetic resonance image (14 July 2022). Contrast-enhanced abdominal magnetic resonance image (6 August 2022). Contrast-enhanced abdominal magnetic resonance image (7 October 2022). Contrast-enhanced abdominal magnetic resonance image (3 December 2022). Contrast-enhanced abdominal magnetic resonance image (7 February 2023). Pathology: Breast high-grade DCIS and liver metastatic adenocarcinoma were confirmed by pathology and IHC (Figures 14–17). DCIS with microinvasion is often considered a borderline between in situ and invasive disease, but this case had no definite microinvasion.5Figure 14Pathological image of breast mass.Micrograph: two purple cell nests in pink stroma, surrounded by clear adipose spaces.A micrograph displays a tissue section with pink and purple staining. Two rounded, well-circumscribed cellular nests occupy the central area, each composed of densely packed cells with numerous small, dark purple nuclei and scant pale cytoplasm. The right nest contains a more intensely purple central zone compared with its peripheral portion, while the left nest has a more uniform nuclear density. Both nests are bordered by a thin rim of paler pink connective tissue. The surrounding background consists of broad bands of pink fibrous stroma containing elongated, spindle-shaped dark nuclei arranged in sweeping, curved bundles around the nests. At the outer edges, multiple large, clear, round to oval spaces with thin pink rims are present, consistent with adipose-type vacuolated areas. No text labels, scale bars, or graphical elements are present.Figure 15Fluorescence in situ hybridization of breast mass.A fluorescence micrograph shows blue round nuclei with scattered red and green puncta on a black background.A fluorescence micrograph with a black background contains many round to oval blue-stained nuclei distributed across the field, with several nuclei overlapping or clustered. Numerous small punctate signals in red and green are dispersed within and around the blue nuclear areas, with some nuclei containing multiple red puncta, multiple green puncta, or both colors. A diffuse yellow-orange glow occupies the lower-left corner, fading into the surrounding dark background. No scale bar, legend, labels, or magnification text is present.Figure 16Pathological image of liver metastasis tumor biopsy.Micrograph: pink/purple stratified squamous epithelium over pale fibrous tissue with scattered nuclei.The micrograph presents a tissue section stained in pink and purple tones. A band of stratified squamous epithelium forms an undulating surface layer, with multiple layers of closely packed, dark purple nuclei and lighter pink cytoplasm. Beneath the epithelium, a broad zone of pale pink fibrous connective tissue contains wavy collagen-like bundles and scattered elongated and round dark purple nuclei. The tissue occupies the lower portion of the field, while the upper portion contains a large light, mostly empty background area. Small detached fragments of similarly stained tissue are present near the upper left and upper right margins. No text, scale bar, or magnification label is present.Figure 17Fluorescence in situ hybridization of liver metastasis tumor biopsy.A micrograph shows blue nuclei clusters with red and green signals on a dark background.A fluorescence micrograph with a dark background contains many closely packed, round to oval blue-stained nuclei distributed across the full field. The nuclei vary in size and overlap in several areas, forming a dense cellular arrangement with minimal empty space between neighboring nuclei. Numerous small red punctate signals occur in multiple nuclei, frequently forming compact clusters of several dots within single nuclei, with some clusters positioned near nuclear edges and others nearer nuclear centers. Additional red puncta occur as smaller groups or isolated dots in a few nuclei. Small green punctate signals are scattered across the field, including within nuclei and in spaces between nuclei, with several nuclei containing one or more green dots. No text labels, legends, arrows, axis markings, or scale bar are present. Pathological image of breast mass. Fluorescence in situ hybridization of breast mass. Pathological image of liver metastasis tumor biopsy. Fluorescence in situ hybridization of liver metastasis tumor biopsy. Timeline: See Figure 18.Figure 18The timeline of this case report.Case report: breast cancer with liver metastases - diagnosis, treatment, ongoing therapy timeline.The timeline of this case report includes several key events: September 2021: Diagnosed with high-grade ductal carcinoma in situ (DCIS; 5.0 cm, HER2-positive) following left simple mastectomy. No adjuvant therapy was administered. January 2022: Multiple hepatic space-occupying lesions were detected on routine follow-up abdominal ultrasound. March 2, 2022: Liver biopsy confirmed metastatic adenocarcinoma, consistent with a breast primary. March 21, 2022: Initiated systemic therapy with the TCbHP regimen (docetaxel, carboplatin, trastuzumab, pertuzumab). After 10 cycles of TCbHP: Achieved complete response of the liver metastases. Ongoing: Continued maintenance therapy with HP (trastuzumab, pertuzumab) and capecitabine, with sustained remission. The timeline of this case report. Discussion Rarity and Mechanism of DCIS Distant Metastasis DCIS distant metastasis is extremely rare with an incidence lower than 0.5%.5 According to systematic literature review, fewer than 100 cases of DCIS distant metastasis have been reported worldwide, and only 15–20% of them are liver metastasis.17 Rare presentations of metastatic breast cancer from stage 0/1 disease, including DCIS, have been reported, but liver metastasis remains uncommon.16 The core pathological mechanism is mostly related to missed microinvasion in the initial pathological diagnosis, which means tumor cells break through the basement membrane with foci ≤1 mm and cannot be identified by routine sampling.5,14 High nuclear grade, large tumor diameter (>3 cm), HER2 positivity, high Ki-67, and young age are the main high-risk factors for DCIS metastasis.19 These factors promote tumor proliferation, angiogenesis, and invasive ability, which increase the risk of early distant metastasis even if the pathological diagnosis is pure DCIS.20 The oncogene HER2 plays a key role in the metastasis of breast cancer, including DCIS, by activating related signaling pathways.20 This case fully conforms to the above high-risk characteristics, which also explains the reason for early liver metastasis after surgery. High-Risk Factors for DCIS Distant Metastasis and Evidence Levels Combined with the latest literature and guidelines (NCCN 3.2024, CSCO 2025),21,22 the recognized high-risk factors for DCIS distant metastasis and evidence levels are summarized as follows: A. High nuclear grade: Evidence level IIA; high-grade DCIS has stronger proliferation and invasion potential.5 B. Tumor diameter >3 cm: Evidence level IIA; large-volume DCIS is more likely to have focal microinvasion.10,19 C. HER2 positivity: Evidence level IB; HER2 overexpression activates PI3K/AKT and MAPK pathways to enhance metastasis.20 D. High Ki-67 expression (≥20%): Evidence level IIB; reflects strong tumor proliferation activity.19 E. Microinvasion: Evidence level IA; microinvasion foci are the direct source of distant metastasis.5 F. Young age (<40 years old): Evidence level IIB; young patients have more active tumor biology.19 This case matches all the above high-risk factors: high grade, tumor size 5.0 cm (>3 cm), HER2 positive, Ki-67 30% (≥20%), young age (35 years old), which is consistent with the high-risk characteristics of DCIS distant metastasis. Treatment Options for DCIS Liver Metastasis and Efficacy DCIS liver metastasis is rare, and its treatment refers to the norms of invasive breast cancer liver metastasis:7,8 Systemic therapy: The first choice for multiple metastases; HER2-positive patients prefer dual-targeted therapy combined with chemotherapy.21,22 Local treatment: Surgical resection or ablation for isolated oligometastases.7,8 Maintenance therapy: Targeted therapy combined with chemotherapy to prolong progression-free survival.21,22 Efficacy of common regimens: HER2-positive metastatic breast cancer: Trastuzumab + pertuzumab + chemotherapy can achieve an objective remission rate (ORR) of 80%–90%, and median progression-free survival (PFS) of 18.7 months.21 TCbHP regimen (docetaxel + carboplatin + trastuzumab + pertuzumab): It is a first-line regimen for HER2-positive metastatic breast cancer with strong efficacy and manageable safety.21 Diagnostic and Therapeutic Highlights of This Case A. Rare event confirmation: This is a typical rare case of liver metastasis from high-risk DCIS, which is rarely reported in domestic and foreign literature.16,17 B. High-risk feature matching: Fully consistent with the recognized high-risk factors of DCIS distant metastasis, providing clinical evidence for risk stratification.21,22 C. Remarkable efficacy of TCbHP regimen: 10 cycles of treatment achieved complete remission of liver metastases, confirming that dual anti-HER2 targeted combined chemotherapy is effective for HER2-positive DCIS liver metastasis.20,21 D. Guideline-based treatment: Treatment intensity refers to invasive breast cancer, verifying the rationality of stratified management of high-risk DCIS.21,22 Limitations This study has several limitations. First, this is a single-case report from a single center, and the conclusion needs to be verified by more cases. Second, the initial pathological section did not find definite microinvasion foci, so the direct cause of metastasis cannot be fully confirmed. Third, the follow-up time is relatively short, and long-term survival data need to be further collected. Clinical Implications A. Pathological diagnosis: For large-volume, high-grade, HER2-positive DCIS, full-sample pathological examination should be performed to exclude microinvasion.5 B. Risk stratification: High-risk DCIS patients should receive close follow-up (abdominal imaging every 3–6 months) to detect metastasis early.10 C. Adjuvant therapy: For HER2-positive, large-volume, high-grade DCIS, adjuvant targeted therapy can be considered to reduce metastasis risk.19,21 D. Metastasis treatment: Once metastasis occurs, systemic therapy based on anti-HER2 dual-targeted therapy should be initiated immediately to improve prognosis.7,8 Conclusions DCIS distant metastasis is extremely rare, and liver metastasis is an uncommon manifestation of metastatic DCIS. High-grade, tumor >3 cm, HER2 positivity, high Ki-67, and young age are independent high-risk factors with moderate-to-high evidence levels. TCbHP regimen has significant efficacy in the treatment of HER2-positive DCIS liver metastasis and can achieve complete remission. High-risk DCIS should adopt stratified management, and treatment intensity should refer to invasive breast cancer to improve prognosis.